Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
Zhao P, Li L, Jiang X, Li Q. · 2019
Read Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. by Zhao P, Li L, Jiang X, Li Q. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6544911.txt.
Description
Zhao, Li, Jiang and Li review a DNA-repair flaw that predicts who gains from cancer immunotherapy, writing in the Journal of Hematology & Oncology. When mismatch repair fails, copying errors pile up at short repeats called microsatellites. Such tumors, labeled dMMR or MSI-high, carry many mutations.
Those mutations create fresh antigens that draw immune attack, so checkpoint drugs work unusually well in these patients. Trials showed long responses in bowel and other cancers alike. Pembrolizumab won approval for any stubborn solid tumor with this flaw — the first cancer approval tied to a marker rather than an organ. The review covers the biology, the trial record, and how this test sits beside PD-L1 and tumor mutation counts.
Catalog record
| CREATOR | Zhao P, Li L, Jiang X, Li Q. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |